MedTrace Logo

Evaluate the Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System

NCT03788590 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2019-01-08

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that transcatheter artificial aortic valve and transcatheter artificial heart values delivery system is associated with a reduction of all-cause mortality in severe aortic stenosis or insufficiency patients who are high risk or ineligible for aortic valve replacement.

Conditions

  • Severe Aortic Stenosis
  • Aortic Regurgitation

Interventions

DEVICE

Jenscare TAVI

Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.

Sponsors & Collaborators

  • Ningbo Jenscare Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Peng Cao, Doctor · Ningbo Jenscare Biotechnology Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-23
Primary Completion
2021-11-23
Completion
2021-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03788590 on ClinicalTrials.gov